Inavolisib now FDA approved based off INAVO120 – Oncology Brothers

Oncology Brothers shared on X:

“Inavolisib now FDA approved based off INAVO120: Ph III, Inavolisib (iPI3Ka) + Fulv + Palbo vs Palbo/Fulvestrant HR+ metastatic breast cancer:

– OS immature (favoring Inavo HR 0.64)

– PFS 15.0 vs 7.3mos (HR 0.43)

– AEs: >50% hyperglycemia and stomatitis.”

Sara Sammons shared a post by Oncology Brothers, on X, adding:

“Nice first step and proof of concept. I’m looking forward to less toxic PIK3CA inhibitors.”

More posts featuring Oncology Brothers and Sara Sammons on oncodaily.com

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families. Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.

Sarah Sammons is a medical oncologist at Dana-Farber’s Breast Oncology Center specializing in treating patients with all stages of breast cancer. She is particularly focusing on improving outcomes for those with metastatic breast cancer. Through leading numerous clinical trials, she has developed new treatment options for breast cancer patients. Additionally, Dr. Sammons is skilled in treating brain metastases.